---
schema_version: "1.0.0"
document_id: "05e017ccac1254b4c1d0ada6ac50a5a1c33211f5b0a6b7acacb0b8f0a95d3ad1"
company_key: "yc-centaur"
company: "Centaur"
source_id: "yc-centaur-news-import-7ab94b327191"
canonical_url: "https://centaur.ai/post/what-ai-medical-device-teams-get-wrong-about-fda-510-k"
published_at: "2026-03-31T14:04:07.528+00:00"
first_seen_at: "2026-07-27T00:36:30.031492+00:00"
fetched_at: "2026-07-28T21:25:41.488077+00:00"
content_hash: "sha256:ef69c6ddc3a552fb0694cd455e0bae87e49fbbb628013dbc92c0f00f738af622"
---

# What AI Medical Device Teams Get Wrong About FDA 510(k)

## **What Teams Get Wrong About FDA 510(k)**


Most teams think FDA clearance is solely about model performance. It is not. The FDA does not evaluate your model in isolation. Essentially, it instead evaluates whether your data, methodology, and documentation support the claims you are making. That is where submissions succeed or fail.
‍


Start with the basics. Devices in the 510(k) pathway are not “approved.” They are[“cleared.”](https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k?utm_source=chatgpt.com) The distinction reflects how the FDA evaluates risk. You are not proving something from scratch. You are demonstrating substantial equivalence to an “legally marketed predicate device.”
‍


## **The Three Paths to Market**


Nearly every AI medical device follows one of three routes:
‍


**1) 510(k) Clearance** : The standard path for most Class II devices. You show that your device is substantially equivalent (and as safe and effective) as a legally marketed product.
‍


**2) PMA (Premarket Approval)** : Required for high-risk devices. This is a full evidentiary burden, often including clinical data, and carries significantly longer timelines.


**3) De Novo Authorization** : Used when no predicate exists. Many early AI devices entered through this pathway. Once established, these classifications often become the foundation for future 510(k) submissions.
‍


## **The Real Risk Is Not Model Accuracy. It Is Data Credibility.**


FDA guidance is consistent on one point: performance metrics alone are not enough. Reviewers look closely at how your data was sourced, how it was labeled, and whether it represents the population your device is intended to serve. If your dataset cannot support those claims, your results are too weak. You need to be able to clearly answer the following:


‍


- Where did this data come from?
- How many sites contributed, and how diverse are they?
- Does the population reflect real-world use?
- How were labels generated, and by whom?


Submissions often slow down not because the model underperforms, but because these questions are not answered cleanly. The FDA also recommends that performance to be evaluated across clinically relevant subgroups, not just as a single aggregate number. If performance varies, you need to show where and why.


‍


## **Expertise Is Not a Checkbox**


Annotation quality is not just about having clinicians involved. It is about having the right clinicians applied in a structured, transparent way. For AI-enabled devices that rely on annotated data, the FDA expects you to document who performed the labeling and what qualifies them to do so. That qualification should directly map to the device's intended use.


‍


If your device operates in a specific clinical domain, your labeling process needs to reflect real clinical expertise in that domain. General credentials are rarely sufficient on their own. Alignment is what matters.


‍


## **Your Methodology Must Withstand the Review Process**


There is no single required methodology, but there is a clear expectation: your process for establishing ground truth must be rigorous, repeatable, and well-documented. In practice, that often means the following:


‍


- Independent review by multiple qualified experts
- A defined process for handling disagreement
- Clear documentation of how final labels are determined


If the disagreement is resolved, the method should be explicit. If variability exists, it needs to be understood. The FDA is not just reviewing your outputs. It is a review of how you arrived at them.


‍


## **Documentation Is Where Good Work Breaks**


Strong data and strong models do not compensate for weak documentation. The FDA may ask you to show exactly how your study was conducted. That includes:


‍


- What tools were used, and how was consistency maintained?
- What training did labelers receive before contributing?
- How are annotations tied back to specific individuals and decisions?
- What qualifications do these individuals hold?


If you cannot produce that evidence, the strength of your underlying work becomes difficult to defend.


‍


## **Where Centaur Can Help**


Too many teams fail because their data cannot withstand scrutiny. Many regulatory challenges trace back to weaknesses in the supporting data, validation approach, or documentation. Centaur is built to solve that problem.


‍


We deliver expert-labeled, de-identified datasets designed for regulatory use, not just experimentation. Our network includes tens of thousands of licensed healthcare professionals across subspecialties, enabling us to match expertise directly to the task at hand.


‍


More importantly, we structure the work the way the FDA expects to see it. Traceable contributors. Representative data. Defined methodologies. Complete documentation. That is what makes a dataset easier to justify in review. In practice, the more clearly your evidence is documented and supported, the smoother the review process is likely to be. And in FDA review, defensibility is what determines whether you move forward or get stuck.


For a demonstration of how Centaur can facilitate your AI model training and evaluation with greater accuracy, scalability, and value, click here:[https://centaur.ai/demo](https://info.centaurlabs.com/demo)
